Journalists huddle around a medic about to administer a dose of Russia’s Sputnik V vaccine at a clinic in the city of Blida, southwest of the Algerian capital, January 30, 2021. (AFP)
Russia’s Sputnik V vaccine is 91.6 percent effective against symptomatic COVID-19, according to an analysis published in The Lancet on Tuesday that independent experts said allayed transparency concerns over the jab, which Moscow is already rolling out.
For more coronavirus news, visit our dedicated page.
NEW—Interim analysis of Russian #COVID19 #vaccine phase 3 trial involving nearly 20,000 participants suggests a two-dose regimen has an efficacy of 91.6% against symptomatic #COVID19. No serious adverse events were deemed to be associated with vaccination. https://t.co/40sM7f2nbS pic.twitter.com/Hzrs34uCWr
— The Lancet (@TheLancet) February 2, 2021
The preliminary findings show that the two-dose Sputnik V “has shown high efficacy” and was well tolerated for participants over 18 in final-stage clinical trials, said co-lead author Inna Dolzhikova of Russia’s Gamaleya National Research center for Epidemiology and Microbiology.
Read more:
Sputnik V vaccine explainer: Everything you need to know after UAE approval
Coronavirus: UAE approves Russia’s Sputnik COVID-19 vaccine for emergency use
Coronavirus: Pfizer or Sputnik? Immunization race prompts calls for choice
